Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954380 | 0.90 | RXFP1 (0.47) | CXCR2RXFP1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL958516 | 0.86 | CXCR2 (0.54) | CXCR2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL956304 | 0.86 | CXCR2 (0.72) | CXCR2PIK3CDPIK3C2BMTORPIK3CG | |
| SCHEMBL956726 | 0.84 | CXCR2 (0.53) | CXCR2 | |
| SCHEMBL954899 | 0.83 | CXCR2 (0.54) | CXCR2MAOB | |
| SCHEMBL957633 | 0.83 | CXCR2 (0.52) | CXCR2MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL959542 | 0.82 | CXCR2 (0.52) | CXCR2ALDH1A1KDM4EPOLBTP53 | |
| SCHEMBL956296 | 0.82 | CXCR2 (0.56) | CXCR2 | |
| SCHEMBL959381 | 0.82 | CXCR2 (0.51) | CXCR2PIK3CG | |
| SCHEMBL3341624 | 0.81 | CXCR2 (0.50) | CXCR2RXFP1MAOBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885RXFP1 89/4885NOS1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.